Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon Dec 05, 2018 11:47am

102 Views

Post# 29068676

RE:This might help clear up things a bit

Stock38 did you attend this meeting? Is this how you understand what they said?

Does anybody feel comfortable with these patient numbers? Is it possible that a proportion of people taking the drug are not paying, eg still few dozen frm EAP? It would make sense that a proportion of the EAP patients still dont have their insurer covering or are part of the slower public process? Its possible that doesnt make sense either.

There seems to be a disconnect here still.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale